Neurotrope 10-Q 13 Nov 15 2015 Q3 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	9 Months Ended
	Sep. 30, 2015	Nov. 12, 2015
Document Information [Line Items]
Entity Registrant Name	Neurotrope, Inc.
Entity Central Index Key	1,513,856
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Trading Symbol	NTRP
Entity Common Stock, Shares Outstanding		28,976,540
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2015
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2,015

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Sep. 30, 2015	Dec. 31, 2014
CURRENT ASSETS
Cash and cash equivalents	$ 1,543,537	$ 8,010,357
Prepaid expenses	347,931	97,073
TOTAL CURRENT ASSETS	1,891,468	8,107,430
Fixed Assets, net of accumulated depreciation	60,786	53,618
TOTAL ASSETS	1,952,254	8,161,048
CURRENT LIABILITIES
Accounts payable	1,010,723	778,753
Accrued expenses	333,315	310,435
Note payable	18,393	0
Accounts payable and accrued expenses - related party	236,547	200,000
TOTAL CURRENT LIABILITIES	$ 1,598,978	$ 1,289,188
Commitments and contingencies
Convertible redeemable preferred stock, Series A, $.0001 par value, 50,000,000 shares authorized; 16,755,894 and 21,363,000 shares issued and outstanding at September 30, 2015 and December 31, 2014, respectively. Liquidation preference of $16,755,894 plus dividends accruable at 8% per annum of $3,139,966 as of September 30, 2015 and Liquidation preference of $21,363,000 plus dividends accruable at 8% per annum of $2,687,835 at December 31, 2014	$ 14,522,010	$ 18,524,163
SHAREHOLDERS' DEFICIT
Common stock - 300,000,000 shares authorized, $.0001 par value; 28,877,540 issued and outstanding at September 30, 2015; 24,034,094 shares issued and outstanding at December 31, 2014	2,888	2,403
Additional paid-in capital	11,019,241	6,627,983
Accumulated deficit	(25,190,863)	(18,282,689)
TOTAL SHAREHOLDERS' DEFICIT	(14,168,734)	(11,652,303)
TOTAL LIABILITIES AND SHAREHOLDERS' DEFICIT	$ 1,952,254	$ 8,161,048

Condensed Consolidated Balance3

Condensed Consolidated Balance Sheets [Parenthetical] - USD ($)	Sep. 30, 2015	Dec. 31, 2014
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized	300,000,000	300,000,000
Common stock, shares issued	28,877,540	24,034,094
Common stock, shares outstanding	28,877,540	24,034,094
Series A Convertible Redeemable Preferred Stock [Member]
Preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	50,000,000	50,000,000
Preferred stock, shares issued	16,755,894	21,363,000
Preferred stock, shares outstanding	16,755,894	21,363,000
Preferred Stock, Liquidation Preference, Value (in dollars)	$ 16,755,894	$ 21,363,000
Dividends Payable Percentage (in percentage)	8.00%	8.00%
Dividends Payable (in dollars)	$ 3,139,966	$ 2,687,835

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
OPERATING EXPENSES:
Research and development - related party	$ 636,547	$ 846,135	$ 1,852,428	$ 1,909,363
Research and development	268,665	368,221	1,348,143	774,189
General and administrative - related party	27,000	27,693	81,000	81,693
General and administrative	817,880	1,307,877	3,242,220	3,174,489
Stock-based compensation - related party	44,299	74,302	131,453	208,569
Stock-based compensation	97,913	520,087	255,774	722,304
TOTAL OPERATING EXPENSES	1,892,304	3,144,315	6,911,018	6,870,607
OTHER INCOME:
Interest income	355	2,707	2,844	11,590
Net loss before income taxes	(1,891,949)	(3,141,608)	(6,908,174)	(6,859,017)
Provision for income taxes	0	0	0	0
Net loss	(1,891,949)	(3,141,608)	(6,908,174)	(6,859,017)
Preferred Stock dividends	(328,034)	(448,869)	(1,002,599)	(1,355,396)
Net loss attributable to common shareholders	$ (2,219,983)	$ (3,590,477)	$ (7,910,773)	$ (8,214,413)
PER SHARE DATA:
Basic and diluted loss per common share (in dollars per share)	$ (0.08)	$ (0.16)	$ (0.30)	$ (0.38)
Basic and diluted weighted average common shares outstanding (in shares)	27,801,000	21,951,000	26,214,000	21,838,000

Condensed Consolidated Stateme5

Condensed Consolidated Statement of Changes in Shareholders' Deficit - 9 months ended Sep. 30, 2015 - USD ($)	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]
Balance at Dec. 31, 2014	$ (11,652,303)	$ 2,403	$ 6,627,983	$ (18,282,689)
Balance (in shares) at Dec. 31, 2014		24,034,094
Conversion of Series A preferred stock to common stock	4,002,153	$ 461	4,001,692	0
Conversion of Series A preferred stock to common stock (in shares)		4,607,106
Stock based compensation	387,227	$ 0	387,227	0
Exercise of common stock warrants	2,363	$ 24	2,339
Exercise of common stock warrants (in shares)		236,340
Net loss	(6,908,174)	$ 0	0	(6,908,174)
Balance at Sep. 30, 2015	$ (14,168,734)	$ 2,888	$ 11,019,241	$ (25,190,863)
Balance (in shares) at Sep. 30, 2015		28,877,540

Condensed Consolidated Stateme6

Condensed Consolidated Statements of Cash Flows - USD ($)	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$ (6,908,174)	$ (6,859,017)
Adjustments to reconcile net loss to net cash used by operating activities
Stock based compensation	387,227	930,873
Consulting services paid by issuance of common stock	0	25,000
Depreciation expense	4,659	613
Change in assets and liabilities
Increase in prepaid expenses	(250,858)	(67,553)
Increase in accounts payable and accrued expenses - related party	36,547	51,749
Increase in accounts payable	231,970	183,919
Increase in accrued expenses	22,880	637,316
Total adjustments	432,425	1,761,917
Net Cash Used in Operating Activities	(6,475,749)	(5,097,100)
CASH FLOWS FROM INVESTING ACTIVITIES
Purchase of property and equipment	(11,827)	(48,720)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from note payable	28,904	0
Repayments on note payable	(10,511)	0
Proceeds from exercise of common stock warrants	2,363	0
Net Cash Provided by Financing Activities	20,756	0
NET DECREASE IN CASH	(6,466,820)	(5,145,820)
CASH AT BEGINNING OF PERIOD	8,010,357	15,211,744
CASH AT END OF PERIOD	$ 1,543,537	$ 10,065,924
DISCLOSURE OF NON-CASH FINANCING ACTIVITIES:
Conversion of Series A convertible redeemable preferred stock to common stock	4,002,153	304,515

Organization and Nature of Plan

Organization and Nature of Planned Business:	9 Months Ended
	Sep. 30, 2015
GENERAL ORGANIZATION AND BUSINESS [Abstract]
Nature of Operations [Text Block]	Note 1 – Organization and Nature of Planned Business : Neurotrope BioScience was incorporated in Delaware on October 31, 2012. Neurotrope BioScience was formed to advance new therapeutic and diagnostic technologies in the field of neurodegenerative disease, primarily Alzheimer’s disease (“AD”). Neurotrope BioScience is collaborating with the Blanchette Rockefeller Neurosciences Institute (“BRNI”), a related party, in this process. The exclusive rights to certain technology were licensed by BRNI to the Company on February 28, 2013 (see Note 6). On August 23, 2013, a wholly-owned subsidiary of Neurotrope, Inc. (formerly “BlueFlash Communications, Inc.”), Neurotrope Acquisition, Inc., a corporation formed in the State of Nevada on August 15, 2013 merged (the “Reverse Merger”) with and into Neurotrope BioScience. Neurotrope BioScience was the surviving corporation in the Reverse Merger and became the Company’s wholly-owned subsidiary. All of the outstanding Neurotrope BioScience common stock was converted into shares of Neurotrope, Inc. common stock on a one-for-one basis. The transaction was accounted for as a reverse merger and recapitalization with Neurotrope BioScience as the acquirer for financial reporting purposes and Neurotrope, Inc. as the acquired company. Consequently, the assets and liabilities and the operations that are reflected in the historical financial statements are those of Neurotrope BioScience and are recorded at the historical cost basis of Neurotrope BioScience, and the consolidated financial statements after completion of the Reverse Merger include the assets and liabilities of Neurotrope BioScience and Neurotrope, Inc., and the historical operations of Neurotrope, Inc. and Neurotrope BioScience from the closing date. As a result of the Reverse Merger, Neurotrope, Inc. discontinued its pre-Reverse Merger business and acquired the business of Neurotrope BioScience, which it is continuing to operate through Neurotrope BioScience. The common stock of Neurotrope, Inc. is traded under the ticker symbol “NTRP.” Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States (U.S. GAAP) have been condensed or omitted. These consolidated financial statements should be read in conjunction with the Consolidated Financial Statements and Notes to the Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended December 31, 2014.

Going Concern_

Going Concern:	9 Months Ended
	Sep. 30, 2015
Going Concern [Abstract]
Going Concern [Text Block]	Note 2 – Going Concern: The unaudited consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. As shown in the consolidated financial statements, we have generated no revenues to-date, have incurred substantial losses and have substantial contractual commitments pursuant to various agreements to which we are a party. Our ability to continue existence is dependent upon our continuing efforts to obtain additional financing to carry out our business plan. We intend to fund our operations through equity and/or debt financing arrangements and any revenues generated in the future. However, there can be no assurance that these arrangements, if any, will be sufficient to fund our ongoing capital expenditures, working capital, and other cash requirements. The outcome of these matters cannot be predicted at this time. There can be no assurance that any additional financings will be available to us on satisfactory terms and conditions, if at all. These conditions raise substantial doubt as to our ability to continue as a going concern. The consolidated financial statements do not include any adjustments related to the recoverability or classification of asset-carrying amounts or the amounts and classification of liabilities that may result should we be unable to continue as a going concern.

Summary of Significant Accounti

Summary of Significant Accounting Policies:	9 Months Ended
	Sep. 30, 2015
SUMMARY OF SIGNIFICANT ACCOUNTING PRACTICES [Abstract]
Significant Accounting Policies [Text Block]	Note 3 - Summary of Significant Accounting Policies : The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Certain reclassifications have been made to the 2014 financial statements to conform to the consolidated 2015 financial statement presentation. These reclassifications had no effect on net loss or cash flows as previously reported. The Company considers all highly liquid temporary cash investments with an original maturity of three months or less when purchased to be cash equivalents. At September 30, 2015, the Company’s cash balances may exceed the current insured amounts under the Federal Deposit Insurance Corporation. Property and equipment is capitalized and depreciated on a straight line basis over the useful life of the asset, which is deemed to be between three and ten years. September 30, December 31, 2015 2014 Property and equipment $ 66,770 $ 54,943 Accumulated depreciation (5,984) (1,325) Property and equipment, net $ 60,786 $ 53,618 Depreciation expense for the nine months ended September 30, 2015 and 2014 was $ 4,659 613 The Company financed its general liability and workers compensation insurance premiums for the insurable period from May 16, 2015 to May 15, 2016. The total principal amount of the unsecured note payable relating to the premiums was $ 31,613 4.12 2,709 2,682 18,393 All research and development costs, including costs to maintain or expand the Company’s patent portfolio licensed from BRNI that do not meet the criteria for capitalization are expensed when incurred. FASB ASC Topic 730 requires companies involved in research and development activities to capitalize non-refundable advance payments for such services pursuant to contractual arrangements because the right to receive those services represents an economic benefit. Such capitalized advances will be expensed when the services occur and the economic benefit is realized. There were no capitalized research and development services at September 30, 2015 and December 31, 2014. Income taxes are provided for the tax effects of transactions reported in the financial statements and consist of taxes currently due and deferred taxes. Deferred taxes are recognized for differences between the bases of assets and liabilities for financial statement and income tax purposes and the tax effects of net operating loss and other carryforwards. The deferred tax assets and liabilities represent the future tax consequences of those differences and carryforwards, which will either be taxable or deductible when the related assets, liabilities or carryforwards are recovered or settled. Deferred tax assets are reduced by a valuation allowance when, based on the weight of available evidence, it is more likely than not that some portion or all of the deferred tax assets will not be realized. The Company applies the provisions of FASB ASC 740-10, Accounting for Uncertain Tax Positions The Company has concluded that there are no significant uncertain tax positions requiring recognition in the accompanying financial statements. The tax period that is subject to examination by major tax jurisdictions is from October 31, 2012 (inception) through September 30, 2015. In the event the Company was to receive an assessment for interest and/or penalties, it will be classified in the financial statements as selling, general and administrative expense when assessed. The Company operates in an industry that is subject to rapid technological change, intense competition and significant government regulation. The Company’s operations are subject to significant risk and uncertainties including financial, operational, technological, regulatory and other risk. Such factors include, but are not necessarily limited to, the results of clinical testing and trial activities, the ability to obtain regulatory approval, the ability to obtain favorable licensing, manufacturing or other agreements for its product candidates and the ability to raise capital to achieve strategic objectives. See Part II, Item 1A, “Risk Factors” of this quarterly report below. The Company accounts for stock-based awards to employees in accordance with applicable accounting principles, which requires compensation expense related to share-based transactions, including employee stock options, to be measured and recognized in the financial statements based on a determination of the fair value of the stock options. The grant date fair value is determined using the Black-Scholes-Merton (“Black-Scholes”) pricing model. For all employee stock options, we recognize expense over the employee’s requisite service period (generally the vesting period of the equity grant). The Company’s option pricing model requires the input of highly subjective assumptions, including the expected stock price volatility, expected term, and forfeiture rate. Any changes in these highly subjective assumptions significantly impact stock-based compensation expense. Options awarded to purchase shares of common stock issued to non-employees in exchange for services are accounted for as variable awards in accordance with applicable accounting principles. Such options are valued using the Black-Scholes option pricing model.

Contractual Commitments_

Contractual Commitments:	9 Months Ended
	Sep. 30, 2015
Contractual Commitments [Abstract]
Contractual Commitments [Text Block]	Note 4 – Contractual Commitments : Effective as of July 16, 2014, the Company’s former President’s employment as Chief Executive Officer and President of Neurotrope BioScience and the Company was terminated. In connection with the termination, effective as of July 16, 2014, Neurotrope BioScience and its former President entered into a separation agreement and general release on October 9, 2014 (the “Separation Agreement”). The Separation Agreement states that Neurotrope BioScience will pay or provide to the former President the following: (a) $ 2,684 233,000 25,478 2,974 17,000 282,000 Effective February 28, 2013, the Company executed an agreement with Ramat Consulting Corp. (“Ramat”), a related party to the Company’s current President and CEO Charles S. Ramat, for consulting services, including business development and marketing consulting, for a five-year period, subject to annual renewals thereafter. The Ramat agreement was amended on February 2, 2015 to add Mr. Ramat’s duties as the Company’s President and CEO. Ramat's annual fee is $ 50,000 4,167 300,000 1.00 20 1,000,000 On October 1, 2013, the Company executed a four-year employment agreement, effective October 1, 2013, with Robert Weinstein, its current Executive Vice President, Chief Financial Officer, Treasurer and Secretary. This agreement provides for an annual salary of $ 240,000 275,000 50 650,000 1.00 25 25 On January 16, 2014, the Company executed a four-year employment letter with Neurotrope BioScience’s former Vice President – Commercial Operations. This employment letter provided for an annual salary of $ 210,000 100,000 1.76 20 40,000 175,000 7.5 175,000 On January 22, 2014, the Company executed a four-year employment agreement with Neurotrope BioScience’s former Vice President and Chief Medical Officer. On October 31, 2014, the Company terminated him without cause. Approximately $ 217,000 On June 1, 2014, the Company executed a four-year employment letter with Neurotrope BioScience’s former Executive Director – Pharmacology. This employment letter provided for an annual salary of $ 180,000 50,000 90,000 7.5 On July 16, 2014, the Board appointed Charles S. Ramat and Paul E. Freiman to serve as Co-Chief Executive Officers, on an interim basis, of the Company and of Neurotrope BioScience. Mr. Freiman has served on the Board since October 18, 2013, and was appointed Co-Chairman of the Board on June 13, 2014. Mr. Ramat was elected to the Board on June 13, 2014 and was immediately appointed Co-Chairman of the Board. In consideration of the services to be provided by Mr. Freiman and Mr. Ramat to the Company as Co-Chief Executive Officers, the Company agreed to pay each of them consulting fees in the amount of $ 20,000 10,000 options to purchase 400,000 shares of the Company’s common stock for their roles as directors, Co-Chairmen of the Board and Co-Chief Executive Officers. Options to purchase 200,000 shares have an exercise price of $1.11 per share, or 110% of the Company’s last trading price on July 23, 2014 and were fully vested upon grant. Options to purchase the remaining 200,000 shares have an exercise price of $2.22 per share based upon two times the exercise price of $1.11 per share and vest on a daily basis up to 25% per year through July 23, 2018 On September 4, 2014, the Company entered into a long-term lease for 4,000 The lease commenced September 1, 2014 and expires December 1, 2017 and has two (2) one-year renewal options. 88,000 On September 12, 2014, the Board elected Mr. Ramat to be the Company’s President and Chief Executive Officer and Mr. Freiman to be the Company’s Chairman of the Board. In consideration of the services that Mr. Ramat will provide to the Company as President and CEO, the Company agreed to pay Mr. Ramat $ 400,000 50 20,000 20,000 50,000 In addition, on September 12, 2014, Messrs. Ramat and Freiman were granted non-qualified options to purchase 250,000 50,000 0.60 As of November 1, 2014, Neurotrope BioScience entered into an employment agreement for one (1) year with provisions for automatic renewals, with its Executive Vice President, Development and Chief Medical Officer. This agreement provided for an annual salary of $ 325,000 102,083 8,507 50 250,000 0.71 20 On April 10, 2015, the Board agreed to grant Mr. Ramat a stock option exercisable for 100,000 10,000,000 On July 1, 2015, Mr. Ramat agreed to defer $ 25,000 50 9,000 50 On September 28, 2015, the Company and Neurotrope BioScience, Inc. consolidated its prior agreements, understandings and commitments into an Employment Agreement with Mr. Ramat to serve as the President and Chief Executive Officer of the Company (the “Employment Agreement). The Employment Agreement supersedes and replaces all such prior agreements, understandings and commitments with respect to Mr. Ramat’s employment and (until its expiration or termination) supersedes and replaces the consulting agreement effective February 28, 2013, as amended, between the Ramat Consulting Group, a related party to Mr. Ramat, and Neurotrope BioScience, Inc. (the “Consulting Agreement”). The consolidation of Agreements did not result in a change to Mr. Ramat’s cash compensation. The Employment Agreement is effective as of September 28, 2015, and has a term of one year with automatic renewals for successive one-year periods unless terminated by either party upon 60 days’ written notice prior to the expiration of the then-current term, or until such employment is earlier terminated in accordance with termination provisions set forth in the Employment Agreement (the “Employment Term”). During the Employment Term, so long as Mr. Ramat is willing to stand for re-election, the Company agreed to nominate him for re-election as a director at the annual meeting (and any other meeting) of stockholders for the election of directors. Under the Employment Agreement, Mr. Ramat is entitled to five weeks of paid vacation per annum and general expense reimbursement for pre-approved business related expenses incurred in the performance of his duties. He will also be eligible for all benefits and retirement, life, disability, medical and dental plan benefits generally available to the Company’s officers in accordance with the terms of those plans. If Mr. Ramat’s employment is terminated for any reason, he is entitled to his accrued benefits. In addition, if his employment is terminated during the Employment Term by the Company for a reason other than Cause (as defined in the Employment Agreement), death or disability, or is terminated by Mr. Ramat for Good Reason (as defined in the Employment Agreement), or as a result of the Company not renewing the Employment Term, in each case, subject to Mr. Ramat’s compliance with certain conditions, then Mr. Ramat is entitled to receive a severance amount equal to his then-current base salary less $50,000 multiplied by 50%, payable in a single lump sum. If Mr. Ramat’s employment is terminated by: (i) the Company for Cause or due to Mr. Ramat’s death or disability, or (ii) by Mr. Ramat without Good Reason, then he is not entitled to any severance, and shall only be entitled to his accrued benefits. The Employment Agreement contains non-competition, non-solicitation and non-disclosure covenants of Mr. Ramat.

Collaborative Agreements_

Collaborative Agreements:	9 Months Ended
	Sep. 30, 2015
Collaborative Agreements [Abstract]
Collaborative Agreements [Text Block]	Note 5 – Collaborative Agreements : On May 12, 2014, the Company entered into a license agreement (the “Stanford Agreement”) with The Board of Trustees of The Leland Stanford Junior University (“Stanford”), pursuant to which Stanford has granted to the Company a revenue-bearing, world-wide right and exclusive license, with the right to grant sublicenses (on certain conditions), under certain patent rights and related technology for the use of bryostatin structural derivatives, known as “bryologs,” for use in the treatment of central nervous system disorders, lysosomal storage diseases, stroke, cardio protection and traumatic brain injury, for the life of the licensed patents. Pursuant to the Stanford Agreement, in 2014, the Company paid Stanford a total of $ 60,850 48,564 10,000 3,700,000 10,000 Each party has the right to terminate the Stanford Agreement for an uncured material breach of the other party. Additionally, the Company may terminate the Stanford Agreement at any time upon 60 days’ written notice to Stanford. On May 15, 2014, the Company entered into an agreement with a contract research organization (“CRO”) to conduct a clinical trial relating to AD. The Company had agreed to pay fees to the CRO totaling $ 715,159 657,238 687,112 377,225 417,877 On July 14, 2014, Neurotrope BioScience entered into an Exclusive License Agreement (the “Mount Sinai Agreement”) with the Icahn School of Medicine at Mount Sinai (“Mount Sinai”). Pursuant to the Mount Sinai Agreement, Mount Sinai granted Neurotrope BioScience a revenue-bearing, world-wide right and (a) exclusive license, with the right to grant sublicenses (on certain conditions), under Mount Sinai’s interest in certain joint patents held by the Company and Mount Sinai (the “Joint Patents”) as well as in certain results and data (the “Data Package”) and (b) non-exclusive license, with the right to grant sublicenses on certain conditions, to certain technical information, both relating to the diagnostic, prophylactic or therapeutic use for treating diseases or disorders in humans relying on activation of PKC epsilon, which includes Niemann-Pick C Disease (the “Mount Sinai Field of Use”). The Mount Sinai Agreement allows Neurotrope BioScience to research, discover, develop, make, have made, use, have used, import, lease, sell, have sold and offer certain products, processes or methods that are covered by valid claims of Mount Sinai’s interest in the Joint Patents or an Orphan Drug Designation Application covering the Data Package (“Mount Sinai Licensed Product(s)”) in the Mount Sinai Field of Use. Pursuant to the Mount Sinai Agreement, Neurotrope BioScience is obligated to pay a $ 25,000 10,000 3,500,000 25,000 11,458 13,542 10,000 Each party has the right to terminate the Mount Sinai Agreement for an uncured material breach of the other party. Additionally, Neurotrope BioScience may terminate the Mount Sinai Agreement at any time upon 60 days’ written notice to Mount Sinai. Further, upon termination, Neurotrope BioScience may continue to sell any and all Mount Sinai Licensed Products, provided that Neurotrope BioScience will pay Mount Sinai a reduced royalty for Mount Sinai Licensed Products that are indicated as therapeutics or diagnostics for Niemann Pick disease which are sold following the termination of the Mount Sinai Agreement. The term of the Mount Sinai Agreement began upon signing and will expire with respect to each Mount Sinai Licensed Product on a Mount Sinai Licensed Product-by-Mount Sinai Licensed Product basis and country-by-country basis, from first commercial sale until the later of: (a) expiration of the last to expire Joint Patent Rights covering such Mount Sinai Licensed Product in such country; (b) expiration of any market exclusivity period granted by a regulatory agency with respect to such Mount Sinai Licensed Product in such country; or (c) ten years after the first commercial sale of such Mount Sinai Licensed Product in such country. On March 30, 2015, Neurotrope Bioscience signed a letter of intent with Worldwide Clinical Trials (“WCT”) to commence pre-patient enrollment activities for the conduct of a Phase 2b clinical trial of the Company’s compound, bryostatin-1, for the treatment of Alzheimer’s disease. The letter of intent, which has subsequently expired, outlined the scope of the services that WCT provided to the Company in relation to the expected Phase 2b clinical trial, as well as additional services that WCT expects to provide once the clinical trial is initiated after the Company obtains additional financing. The Company paid WCT approximately $ 300,000

Related Party Transactions and

Related Party Transactions and Licensing / Research Agreements:	9 Months Ended
	Sep. 30, 2015
Related Party Transactions [Abstract]
Related Party Transactions Disclosure [Text Block]	Note 6 – Related Party Transactions and Licensing / Research Agreements Two directors of the Company, James Gottlieb and William Singer, are also directors of BRNI. Mr. Singer is the president of BRNI. BRNI is a stockholder of a corporation, Neuroscience Research Ventures, Inc. (“NRVI”), which owned 31.1 Effective October 31, 2012, Neurotrope BioScience executed a Technology License and Services Agreement with BRNI, a related party, and NRV II, LLC, another affiliate of BRNI (the “TLSA”), which was previously amended by Amendment No. 1 to the TLSA as of August 21, 2013. As of February 4, 2015, the parties entered into an Amended and Restated Technology License and Services Agreement (the “BRNI License Agreement”). The BRNI License Agreement further amended and restated the TLSA, as amended. Under the terms of the BRNI License Agreement, BRNI provides research services and granted Neurotrope BioScience the exclusive and nontransferable license right to certain patent and intellectual property which became effective upon the Neurotrope BioScience’s completion of a Series A Preferred Stock financing generating net proceeds to Neurotrope BioScience of at least $ 8,000,000 After the initial Series A Preferred Stock financing, the BRNI License Agreement requires Neurotrope BioScience to enter into scope of work agreements with BRNI as the preferred service provider, for any research and development services or other related scientific assistance and support services. Neurotrope BioScience is not permitted to engage any other person other than BRNI to perform research or development services or other related scientific assistance without prior written consent of BRNI, except under certain circumstances. BRNI and Neurotrope may agree to have a third party provide services identical or similar to such services to Neurotrope in the case where BRNI is demonstrably unable to do so or such third party is demonstrably in a superior position to do so. In addition, the BRNI License Agreement requires the Company to pay BRNI a “Fixed Research Fee,” commencing the date that the Company completes a Series B Preferred Stock financing resulting in net proceeds of at least $ 25,000,000 1,000,000 1,000,000 The BRNI License Agreement also requires the payment of royalties ranging between 2 5 5 Pursuant to the BRNI License Agreement, on February 4, 2015, Neurotrope BioScience and BRNI entered into a new Statement of Work and Account Satisfaction Agreement, or the February 2015 SOW. The February 2015 SOW is effective as of October 1, 2014 and ended on September 30, 2015. Pursuant to the February 2015 SOW, Neurotrope BioScience agreed to pay BRNI $ 2,400,000 200,000 600,000 400,000 200,000 20,000 5,000 In consideration for the February 2015 SOW, BRNI agreed to (a) use commercially reasonable efforts to enroll at least four (4) additional compassionate use or expanded access patients, in trials of BRNI’s Alzheimer’s therapeutic drug platform during the term of the SOW, (b) perform certain services requested by Neurotrope BioScience for the further development of BRNI’s Alzheimer’s therapeutic drug platform, (c) perform certain services for the further development of BRNI’s Alzheimer’s diagnostic test, (d) to the extent permitted by applicable law, transfer all of its rights and regulatory obligations, except for those relating to the compassionate use expanded access trials, associated with BRNI’s Investigative New Drug Application (IND) 71,276 to Neurotrope BioScience, (e) conduct initial research on the application of its PKC epsilon platform to treat Fragile X disease, (f) conduct initial research on polyunsaturated fatty acid derivatives for the purpose of developing a commercially usable PKC epsilon activator, and (g) provide assistance, advice and other similar services to Neurotrope BioScience regarding Neurotrope BioScience’s analysis of bryologs pursuant to Neurotrope BioScience’s agreement with Stanford University, for the purpose of developing a commercially usable PKC epsilon activator. Furthermore, BRNI agreed to transfer a certain amount of bryostatin drug substance and bryostatin kits containing drug substance for non-human use to a third-party for storage and handling for Neurotrope BioScience’s pre-clinical and clinical use, which was completed on March 10, 2015. In order for BRNI to perform certain of the services described in (c) above, Neurotrope BioScience reimbursed a third party for services BRNI received from such third party in the amount of $ 150,000 Under the BRNI License Agreement, Neurotrope BioScience received a license to certain technology, including rights relating to an in vitro test system based on examination of skin cells intended to predict the presence of Alzheimer’s disease in humans (the “AD Diagnostic Test”). Further, under the February 2015 SOW, Neurotrope BioScience’s rights to the technology associated with the AD Diagnostic Test automatically reverted to BRNI based on certain contractual conditions on July 10, 2015. The remaining terms and conditions of the BRNI License Agreement, including the license of technology associated with Neurotrope BioScience’s PKC activator research (such as bryostatin), remain in full force and effect, in accordance with the conditions thereof. For the nine months ended September 30, 2015, Neurotrope BioScience incurred $ 1,852,428 See Note 4 for additional related party transactions.

Income Taxes_

Income Taxes:	9 Months Ended
	Sep. 30, 2015
Income Tax Disclosure [Abstract]
Income Tax Disclosure [Text Block]	Note 7– Income Taxes : The Company incurred a net operating loss for income tax purposes of $ 20,184,163 388,000

Common Stock_

Common Stock:	9 Months Ended
	Sep. 30, 2015
STOCKHOLDERS' EQUITY [Abstract]
Stockholders Equity Note Disclosure [Text Block]	Note 8 – Common Stock: During the nine months ended September 30, 2015, 36 holders of 4,607,106 4,607,106 236,340 0.01 236,340 1,637,000 1,637,000 613,228 0.01 613,228

Preferred Stock_

Preferred Stock:	9 Months Ended
	Sep. 30, 2015
Equity [Abstract]
Preferred Stock [Text Block]	Note 9 – Preferred Stock: As of September 2, 2014, the Company and the holders of a majority of the Company’s Series A Preferred Stock entered into an amendment (the “Amendment”) to the Preferred Stockholders Agreement, dated as of August 23, 2013 (the “Preferred Stockholder Agreement”). Under the terms of the Amendment, the parties removed provisions relating to the right of first refusal and certain prohibitions relating to transfers, which were set forth in the Preferred Stockholder Agreement. In addition, the parties made other technical changes to the terms of the Preferred Stockholder Agreement.

Stock Options_

Stock Options:	9 Months Ended
	Sep. 30, 2015
Share-based Compensation Arrangement by Share-based Payment Award, Additional General Disclosures [Abstract]
Stock Option Note Disclosure [Text Block]	Note 10 – Stock Options : Our Board of Directors adopted, and our stockholders approved, the 2013 Plan, which provided for the issuance of incentive awards of up to 7,000,000 5,154,404 3,500,000 54,404 1.75 100 1,050,000 250,000 1.00 20 300,000 1.00 20 On January 23, 2014, the Company issued, under the 2013 Plan, 300,000 1.76 30,000 2.30 20 On July 16, 2014, the Company issued incentive stock options to purchase 50,000 1.24 20 On July 23, 2014, the Company’s Board, and on June 9, 2015, the stockholders, approved increasing the total shares available under the 2013 Plan by 3,000,000 10,000,000 Also, on July 23, 2014, the Board granted non-qualified stock options to three directors, each in the amount of 100,000 shares of common stock; 50,000 of which have an exercise price equal to $1.11, which vested on the date of the grant hereof; and 50,000 of which have an exercise price equal to two times the value of the exercise price of the first 50,000 options, or $2.22 which vest daily over four (4) years (assuming continued service on behalf of the Company), up to 25% per year, until the grant is fully vested on July 23, 2018. On September 12, 2014, the Board granted the Company’s Chief Executive Officer and Chairman non-qualified options to purchase 250,000 50,000 0.60 300,000 0.60 On March 19, 2015, the Company issued stock options to purchase 20,000 1.17 20 50,000 1.17 As of September 30, 2015, the consultant’s options terminated with no vested options exercised based upon the consultant not renewing its consulting agreement with the Company. A summary of the Company’s stock option activity for the nine months ending September 30, 2015 is as follows: Options Weighted-Average Outstanding Exercise Price Outstanding at January 1, 2015 7,769,202 $ 1.40 Options granted 70,000 $ 1.17 Options forfeited (101,250) $ (1.24) Options exercised 0 0 Outstanding at September 30, 2015 7,737,952 $ 1.40 Options exercisable September 30, 2015 5,037,863 $ 1.48 The weighted-average remaining contractual term of options exercisable and outstanding at September 30, 2015 was approximately up to 7.8 8.2 The Company used the Black-Scholes valuation model to calculate the fair value of stock options. Stock-based compensation expense is recognized over the vesting period using the straight-line method. The fair value of stock options issued for the nine months ended September 30, 2015 was estimated at the grant date using the following weighted average assumptions: Dividend yield 0 91.85 1.98 1.02 The total stock option-based compensation recorded as operating expense was $ 387,227 930,873 On September 28, 2015, the Company’s Board of Directors amended options granted to all its officers and directors to reflect that all vested options expire at the end of the options term.

Common and Preferred Stock Rese

Common and Preferred Stock Reserved for Future Issuances:	9 Months Ended
	Sep. 30, 2015
Common And Preferred Stock Reserved For Future Issuances [Abstract]
Common And Preferred Stock Reserved For Future Issuances [Text Block]	Note 11 – Common and Preferred Stock Reserved for Future Issuances : Common stock reserved for future issuances consisted of the following at September 30, 2015: Common Stock Reserved Common stock warrants outstanding 1,375,432 Common stock options outstanding 7,737,952 Conversion of Series A Preferred Stock 16,755,894 Total 25,869,278 On February 9, 2015, the holders of placement agent warrants to purchase an aggregate of 1,325,000 1,325,000

Subsequent Events_

Subsequent Events:	9 Months Ended
	Sep. 30, 2015
Subsequent Events [Abstract]
Subsequent Events [Text Block]	Note 12 – Subsequent Events : From October 1 through November 13, 2015, holders of the Company’s Series A Preferred Stock converted a total of 99,000 99,000 On October 9, 2015, Neurotrope BioScience executed a Services Agreement (the “Agreement”) with WCT, effective as of August 31, 2015. The Agreement relates to services for Neurotrope BioScience’s Phase 2b clinical study assessing the safety, tolerability and efficacy of bryostatin in the treatment of moderately severe to severe Alzheimer’s Disease (the “Study”). Pursuant to the terms of the Agreement, WCT will provide services to enroll approximately one hundred and fifty (150) Study subjects. The Company expects that the first Study site will be initiated during the fourth quarter of 2015. The total estimated budget for the services, including pass-through costs, is approximately $11.6 million. Neurotrope BioScience paid WCT an advance payment of $200,000 upon execution of the Agreement. On November 5, 2015, WCT will invoice Neurotrope BioScience for the following advance payments: (i) services fees of approximately $928,000, which will be due within ten (10) days of Neurotrope BioScience’s receipt of such invoice; (ii) pass-through expenses of approximately $268,000, which will be due within ten (10) days of Neurotrope BioScience’s receipt of such invoice; and (iii) investigator/institute fees of approximately $680,000, which will be due within twenty (20) days of Neurotrope BioScience’s receipt of such invoice. Neurotrope BioScience may terminate the Agreement without cause upon sixty (60) days’ prior written notice. Unless earlier terminated under the provisions of the Agreement, the Agreement will expire upon WCT’s completed performance of the services thereunder (including delivery of all the deliverables) and WCT’s receipt of all payments from Neurotrope BioScience that are due under the Agreement. In addition to Neurotrope BioScience’s termination right described above, Neurotrope BioScience may terminate the Agreement immediately due to patient safety or regulatory request. Further, under the Agreement, either Neurotrope BioScience or WCT may terminate the Agreement if the other party materially breaches the Agreement and fails to cure such breach. Additionally, either Neurotrope BioScience or WCT may terminate the Agreement upon notice to the other party if the other party is adjudicated insolvent or petitions for relief under any insolvency, re-organization, receivership, liquidation, compromise, or any moratorium statute. Also, in connection with the execution of the Agreement, Neurotrope BioScience received consent and is negotiating a Statement of Work pursuant to its BRNI License Agreement. The Statement of Work must be entered into by December 1, 2015 (which date can be extended by mutual agreement of the parties), or BRNI’s consent to the Agreement shall be withdrawn.

Summary of Significant Accoun19

Summary of Significant Accounting Policies: (Policies)	9 Months Ended
	Sep. 30, 2015
SUMMARY OF SIGNIFICANT ACCOUNTING PRACTICES [Abstract]
Use of Estimates, Policy [Policy Text Block]	Use of Estimates: The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
Reclassification, Policy [Policy Text Block]	Reclassifications: Certain reclassifications have been made to the 2014 financial statements to conform to the consolidated 2015 financial statement presentation. These reclassifications had no effect on net loss or cash flows as previously reported.
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash and Cash Equivalents: The Company considers all highly liquid temporary cash investments with an original maturity of three months or less when purchased to be cash equivalents. At September 30, 2015, the Company’s cash balances may exceed the current insured amounts under the Federal Deposit Insurance Corporation.
Property, Plant and Equipment, Policy [Policy Text Block]	Property and Equipment: Property and equipment is capitalized and depreciated on a straight line basis over the useful life of the asset, which is deemed to be between three and ten years. September 30, December 31, 2015 2014 Property and equipment $ 66,770 $ 54,943 Accumulated depreciation (5,984) (1,325) Property and equipment, net $ 60,786 $ 53,618 Depreciation expense for the nine months ended September 30, 2015 and 2014 was $ 4,659 613
Notes Payable [Policy Text Block]	Note Payable: The Company financed its general liability and workers compensation insurance premiums for the insurable period from May 16, 2015 to May 15, 2016. The total principal amount of the unsecured note payable relating to the premiums was $ 31,613 4.12 2,709 2,682 18,393
Research and Development Expense, Policy [Policy Text Block]	Research and Development Costs: All research and development costs, including costs to maintain or expand the Company’s patent portfolio licensed from BRNI that do not meet the criteria for capitalization are expensed when incurred. FASB ASC Topic 730 requires companies involved in research and development activities to capitalize non-refundable advance payments for such services pursuant to contractual arrangements because the right to receive those services represents an economic benefit. Such capitalized advances will be expensed when the services occur and the economic benefit is realized. There were no capitalized research and development services at September 30, 2015 and December 31, 2014.
Income Tax, Policy [Policy Text Block]	Income Taxes: Income taxes are provided for the tax effects of transactions reported in the financial statements and consist of taxes currently due and deferred taxes. Deferred taxes are recognized for differences between the bases of assets and liabilities for financial statement and income tax purposes and the tax effects of net operating loss and other carryforwards. The deferred tax assets and liabilities represent the future tax consequences of those differences and carryforwards, which will either be taxable or deductible when the related assets, liabilities or carryforwards are recovered or settled. Deferred tax assets are reduced by a valuation allowance when, based on the weight of available evidence, it is more likely than not that some portion or all of the deferred tax assets will not be realized. The Company applies the provisions of FASB ASC 740-10, Accounting for Uncertain Tax Positions The Company has concluded that there are no significant uncertain tax positions requiring recognition in the accompanying financial statements. The tax period that is subject to examination by major tax jurisdictions is from October 31, 2012 (inception) through September 30, 2015. In the event the Company was to receive an assessment for interest and/or penalties, it will be classified in the financial statements as selling, general and administrative expense when assessed.
Income Tax Uncertainties, Policy [Policy Text Block]	Risks and Uncertainties: The Company operates in an industry that is subject to rapid technological change, intense competition and significant government regulation. The Company’s operations are subject to significant risk and uncertainties including financial, operational, technological, regulatory and other risk. Such factors include, but are not necessarily limited to, the results of clinical testing and trial activities, the ability to obtain regulatory approval, the ability to obtain favorable licensing, manufacturing or other agreements for its product candidates and the ability to raise capital to achieve strategic objectives. See Part II, Item 1A, “Risk Factors” of this quarterly report below.
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]	Stock Compensation: The Company accounts for stock-based awards to employees in accordance with applicable accounting principles, which requires compensation expense related to share-based transactions, including employee stock options, to be measured and recognized in the financial statements based on a determination of the fair value of the stock options. The grant date fair value is determined using the Black-Scholes-Merton (“Black-Scholes”) pricing model. For all employee stock options, we recognize expense over the employee’s requisite service period (generally the vesting period of the equity grant). The Company’s option pricing model requires the input of highly subjective assumptions, including the expected stock price volatility, expected term, and forfeiture rate. Any changes in these highly subjective assumptions significantly impact stock-based compensation expense. Options awarded to purchase shares of common stock issued to non-employees in exchange for services are accounted for as variable awards in accordance with applicable accounting principles. Such options are valued using the Black-Scholes option pricing model.

Summary of Significant Accoun20

Summary of Significant Accounting Policies: (Tables)	9 Months Ended
	Sep. 30, 2015
SUMMARY OF SIGNIFICANT ACCOUNTING PRACTICES [Abstract]
Property, Plant and Equipment [Table Text Block]	Property and equipment consist of the following: September 30, December 31, 2015 2014 Property and equipment $ 66,770 $ 54,943 Accumulated depreciation (5,984) (1,325) Property and equipment, net $ 60,786 $ 53,618

Stock Options_ (Tables)

Stock Options: (Tables)	9 Months Ended
	Sep. 30, 2015
Share-based Compensation Arrangement by Share-based Payment Award, Additional General Disclosures [Abstract]
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	A summary of the Company’s stock option activity for the nine months ending September 30, 2015 is as follows: Options Weighted-Average Outstanding Exercise Price Outstanding at January 1, 2015 7,769,202 $ 1.40 Options granted 70,000 $ 1.17 Options forfeited (101,250) $ (1.24) Options exercised 0 0 Outstanding at September 30, 2015 7,737,952 $ 1.40 Options exercisable September 30, 2015 5,037,863 $ 1.48

Common and Preferred Stock Re22

Common and Preferred Stock Reserved for Future Issuances: (Tables)	9 Months Ended
	Sep. 30, 2015
Common And Preferred Stock Reserved For Future Issuances [Abstract]
Schedule of Guarantor Obligations [Table Text Block]	Common stock reserved for future issuances consisted of the following at September 30, 2015: Common Stock Reserved Common stock warrants outstanding 1,375,432 Common stock options outstanding 7,737,952 Conversion of Series A Preferred Stock 16,755,894 Total 25,869,278

Summary of Significant Accoun23

Summary of Significant Accounting Policies: (Details) - USD ($)	Sep. 30, 2015	Dec. 31, 2014
Property, Plant and Equipment [Line Items]
Property and equipment	$ 66,770	$ 54,943
Accumulated depreciation	(5,984)	(1,325)
Property and equipment, net	$ 60,786	$ 53,618

Summary of Significant Accoun24

Summary of Significant Accounting Policies: (Details Textual) - USD ($)	1 Months Ended		9 Months Ended
	Jun. 15, 2015	May. 16, 2015	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2014
Summary Of Significant Accounting Policies [Line Items]
Depreciation, Depletion and Amortization			$ 4,659	$ 613
Notes Payable, Current, Total		$ 31,613	$ 18,393		$ 0
Debt Instrument, Periodic Payment, Principal	$ 2,682	$ 2,709
Short-term Debt, Percentage Bearing Fixed Interest Rate		4.12%

Contractual Commitments_ (Detai

Contractual Commitments: (Details Textual)

Apr. 10, 2015USD ($)shares

Nov. 01, 2014USD ($)$ / sharesshares

Oct. 09, 2014USD ($)

Sep. 12, 2014USD ($)$ / sharesshares

Jun. 01, 2014USD ($)

Jun. 17, 2015USD ($)

Feb. 28, 2015USD ($)

Sep. 04, 2014USD ($)ft²

Jul. 16, 2014USD ($)shares

Jan. 23, 2014$ / sharesshares

Jan. 16, 2014USD ($)

Oct. 30, 2013USD ($)$ / sharesshares

Feb. 28, 2013USD ($)$ / sharesshares

Sep. 30, 2015USD ($)shares

Dec. 31, 2014USD ($)

Contractual Commitments And Contingencies [Line Items]

Area of Land | ft²

4,000

Description of Lessor Leasing Arrangements, Operating Leases

The lease commenced September 1, 2014 and expires December 1, 2017 and has two (2) one-year renewal options.

Accrued Rent

$ 88,000

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross | shares

1.24

70,000

Restructuring and Related Cost, Description

Mr. Ramat is entitled to receive a severance amount equal to his then-current base salary less $50,000 multiplied by 50%, payable in a single lump sum

License Maintenance Fee

$ 10,000

Percentage of Vested Options

20.00%

Vice President - Commercial Operations [Member]

Contractual Commitments And Contingencies [Line Items]

Severance Costs

175,000

Ramat [Member]

Contractual Commitments And Contingencies [Line Items]

Consulting Fees

$ 400,000

$ 20,000

$ 50,000

Service Cost Paid Under Installment

$ 4,167

Stock Option Entitled To Related Party | shares

300,000

Stock Option Entitled To Related Party Purchase Price Per Share | $ / shares

$ 1

Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage

20.00%

Targeted Bonus Percentage Of Base Consulting Fees

50.00%

Consulting Fees Total

$ 50,000

Deferred Compensation Arrangement with Individual, Cash Award Granted, Amount

$ 25,000

Targeted Value Of Financing Options

$ 10,000,000

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross | shares

100,000

Freiman [Member]

Contractual Commitments And Contingencies [Line Items]

Consulting Fees

$ 20,000

Freiman And Ramat [Member]

Contractual Commitments And Contingencies [Line Items]

Consulting Fees

20,000

Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price | $ / shares

$ 0.60

Consulting Fees Reduced Amount

$ 10,000

Share-based Compensation Arrangement by Share-based Payment Award, Description

options to purchase 400,000 shares of the Companys common stock for their roles as directors, Co-Chairmen of the Board and Co-Chief Executive Officers. Options to purchase 200,000 shares have an exercise price of $1.11 per share, or 110% of the Companys last trading price on July 23, 2014 and were fully vested upon grant. Options to purchase the remaining 200,000 shares have an exercise price of $2.22 per share based upon two times the exercise price of $1.11 per share and vest on a daily basis up to 25% per year through July 23, 2018

Executive Director - Pharmacology [Member]

Contractual Commitments And Contingencies [Line Items]

Annual Salary Providing Under Agreement

$ 180,000

Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period | shares

50,000

Severance Costs

$ 90,000

Excess Of Additional paid In Capital

$ 7,500,000

Board of Directors Chairman [Member]

Contractual Commitments And Contingencies [Line Items]

Deferred Compensation Arrangement with Individual, Cash Awards Granted, Percentage

50.00%

Noninterest Expense Directors Fees

$ 9,000

Employment Contracts [Member] | Vice President - Commercial Operations [Member]

Contractual Commitments And Contingencies [Line Items]

Annual Salary Providing Under Agreement

$ 210,000

Employment Contracts [Member] | Chief Medical Officer and Vice President [Member]

Contractual Commitments And Contingencies [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage

20.00%

Salaries, Wages and Officers' Compensation

$ 325,000

Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized | shares

250,000

Deferred Compensation Arrangement with Individual, Exercise Price | $ / shares

$ 0.71

Employment Contracts [Member] | Chief Financial Officer [Member]

Contractual Commitments And Contingencies [Line Items]

Targeted Bonus Percentage Of Base Salary

50.00%

Employment Contracts [Member] | Executive Vice President [Member] | Deferred Bonus [Member]

Contractual Commitments And Contingencies [Line Items]

Monthly Signing Bonus

$ 8,507

Salaries, Wages and Officers' Compensation

$ 102,083

Deferred Compensation Arrangement with Individual, Cash Awards Granted, Percentage

50.00%

Employment Contracts [Member] | Robert Weinstein [Member]

Contractual Commitments And Contingencies [Line Items]

Annual Salary Providing Under Agreement

$ 240,000

Increasing In Annual Salary

$ 275,000

Employment Contracts [Member] | Qualifed Stock Option [Member] | Vice President - Commercial Operations [Member]

Contractual Commitments And Contingencies [Line Items]

Share Based Compensation Arrangement By Share Based Payment Award Options Vested Percentage

20.00%

Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period | shares

100,000

Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price | $ / shares

$ 1.76

Severance Costs

$ 175,000

$ 40,000

Excess Of Additional paid In Capital

$ 7,500,000

Employment Contracts [Member] | Qualifed Stock Option [Member] | Chief Medical Officer and Vice President [Member]

Contractual Commitments And Contingencies [Line Items]

Severance Costs

$ 217,000

Employment Contracts [Member] | Qualifed Stock Option [Member] | Robert Weinstein [Member]

Contractual Commitments And Contingencies [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage

25.00%

25.00%

Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period | shares

650,000

Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price | $ / shares

$ 1

Non-Qualified Stock Options [Member] | Ramat [Member]

Contractual Commitments And Contingencies [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period | shares

250,000

Non-Qualified Stock Options [Member] | Freiman [Member]

Contractual Commitments And Contingencies [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period | shares

50,000

Separation Agreement [Member] | Former President [Member]

Contractual Commitments And Contingencies [Line Items]

Reimbursement Of Attorney Fee

$ 17,000

Deferred Compensation Arrangement with Individual, Compensation Expense

2,684

Deferred Compensation Arrangement with Individual, Cash Award Granted, Amount

233,000

Accrued Vacation

$ 25,478

Supplemental Unemployment Benefits, Continuation of Health Care

$ 2,974

Deferred Compensation Arrangement with Individual, Distributions Paid

$ 282,000

Series A Preferred Stock [Member] | Ramat [Member]

Contractual Commitments And Contingencies [Line Items]

Stock Option Entitled To Related Party | shares

1,000,000

Collaborative Agreements_ (Deta

Collaborative Agreements: (Details Textual) - USD ($)	May. 15, 2014	Mar. 30, 2015	Nov. 19, 2014	Jun. 30, 2014	Sep. 30, 2015	Dec. 31, 2014
Contract Research Organization [Member]
Collaborative Agreements [Line Items]
Commitment To Pay Fees	$ 715,159
Reduction Of Commitment Fees			$ 657,238
Payments for Fees					$ 687,112
Accounts Payable					377,225	$ 417,877
Worldwide Clinical Trials [Member]
Collaborative Agreements [Line Items]
Professional Fees		$ 300,000
Stanford Agreement [Member]
Collaborative Agreements [Line Items]
License Initiation Fee						60,850
Annual License Maintenance Fee					10,000	10,000
Milestone Payments Upon Achievement Of Certain Product						3,700,000
Payment For License Agreement Fees				$ 48,564
Mount Sinai Agreement [Member]
Collaborative Agreements [Line Items]
License Initiation Fee					25,000	25,000
Annual License Maintenance Fee					10,000
Milestone Payments Upon Achievement Of Certain Product					3,500,000
Payment For License Agreement Fees					$ 13,542	$ 11,458

Related Party Transactions an27

Related Party Transactions and Licensing / Research Agreements: (Details Textual) - USD ($)	1 Months Ended		3 Months Ended		9 Months Ended
	Feb. 28, 2015	Feb. 28, 2013	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2014
Related Party Transaction [Line Items]
Proceeds from Issuance of Preferred Stock and Preference Stock		$ 8,000,000
Technology Services Costs					$ 1,852,428
Research and Development Expense, Total			$ 268,665	$ 368,221	1,348,143	$ 774,189
Due to Related Parties, Current			236,547		236,547		$ 200,000
Service Fees Third Party					150,000
BRNI License Agreement [Member]
Related Party Transaction [Line Items]
Research and Development Expense, Total					1,000,000
Payments for Fees	$ 2,400,000
Accounts Payable, Other, Current	200,000
Due to Related Parties, Current	$ 600,000
Repayments of Related Party Debt			$ 5,000		20,000
Fixed Research Fee [Member]
Related Party Transaction [Line Items]
Research and Development Expense, Total					$ 1,000,000
Services Reimbursement [Member]
Related Party Transaction [Line Items]
Royalties Percentage					5.00%
Services Reimbursement [Member] | Minimum [Member]
Related Party Transaction [Line Items]
Royalties Percentage					2.00%
Services Reimbursement [Member] | Maximum [Member]
Related Party Transaction [Line Items]
Royalties Percentage					5.00%
Statement Of Work Agreement [Member]
Related Party Transaction [Line Items]
Payments for Fees					$ 200,000	$ 400,000
Series B Preferred Stock [Member] | Fixed Research Fee [Member]
Related Party Transaction [Line Items]
Proceeds from Issuance of Preferred Stock and Preference Stock					$ 25,000,000
President [Member]
Related Party Transaction [Line Items]
Equity Method Investment, Ownership Percentage			31.10%		31.10%

Income Taxes_ (Details Textual)

Income Taxes: (Details Textual)	36 Months Ended
	Sep. 30, 2015USD ($)
Income Tax Expenses Benefit [Line Items]
Operating Income (Loss)	$ 20,184,163
Deferred Tax Assets, Net	$ 388,000

Common Stock_ (Details Textual)

Common Stock: (Details Textual) - $ / shares	9 Months Ended	12 Months Ended
	Sep. 30, 2015	Dec. 31, 2014
Class of Stock [Line Items]
Conversion of Stock, Shares Converted	4,607,106	1,637,000
Convertible Preferred Stock, Shares Issued upon Conversion	4,607,106	1,637,000
Neurotrope Inc. [Member] | Common Stock [Member]
Class of Stock [Line Items]
Warrants Exercisable	236,340	613,228
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	236,340	613,228
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.01	$ 0.01

Stock Options_ (Details)

Stock Options: (Details) - $ / shares	1 Months Ended	9 Months Ended
	Jul. 16, 2014	Sep. 30, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding		7,769,202
Options granted	1.24	70,000
Options forfeited		(101,250)
Options exercised		0
Outstanding		7,737,952
Options exercisable		5,037,863
Weighted-Average Exercise Price, Outstanding		$ 1.40
Weighted-Average Exercise Price, Options granted		1.17
Weighted - Average Exercise Price, Options forfeited		(1.24)
Weighted-Average Exercise Price, Options exercised		0
Weighted-Average Exercise Price, Outstanding		1.40
Weighted-Average Exercise Price, Options exercisable		$ 1.48

Stock Options_ (Details Textual

Stock Options: (Details Textual) - USD ($)	Sep. 12, 2014	Mar. 19, 2015	Jul. 23, 2014	Jul. 16, 2014	Mar. 21, 2014	Jan. 23, 2014	Sep. 30, 2015	Sep. 30, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price							$ 1.48
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate							0.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate							91.85%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate							1.98%
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value							$ 1.02
Employee Benefits and Share-based Compensation							$ 387,227	$ 930,873
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term							7 years 9 months 18 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term							8 years 2 months 12 days
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price							$ 1.17
Consultant One [Member] | Option Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period		50,000
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price		$ 1.17
Director [Member] | Non-Qualified Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period	300,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price	$ 0.60
Three Employee [Member] | Plan 2013 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period						300,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price						$ 1.76
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights						125,000 of these options vest 25% per year, with accelerated vesting of 25% upon a termination without cause or for good reason, with the remaining 175,000 vesting 20% per year.
One Employee [Member] | Plan 2013 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period					30,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price					$ 2.30
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage					20.00%
One Employee [Member] | Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period		20,000
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage		20.00%
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price		$ 1.17
Chief Executive Officer [Member] | Non-Qualified Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period	250,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price	$ 0.60
Chairman [Member] | Non-Qualified Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period	50,000
Equity Incentive Plan 2013 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized							7,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period							5,154,404
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage							20.00%
Share-based Compensation Arrangement by Share-based Payment Award, Description			Also, on July 23, 2014, the Board granted non-qualified stock options to three directors, each in the amount of 100,000 shares of common stock; 50,000 of which have an exercise price equal to $1.11, which vested on the date of the grant hereof; and 50,000 of which have an exercise price equal to two times the value of the exercise price of the first 50,000 options, or $2.22 which vest daily over four (4) years (assuming continued service on behalf of the Company), up to 25% per year, until the grant is fully vested on July 23, 2018
Equity Incentive Plan 2013 [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period			10,000,000
Equity Incentive Plan 2013 [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period			3,000,000
Equity Incentive Plan 2013 [Member] | Founding Stock Holder [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period							3,500,000
Equity Incentive Plan 2013 [Member] | Consultant One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period							54,404
Equity Incentive Plan 2013 [Member] | Founding Stock Holder and Consultant One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price							$ 1.75
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage							100.00%
Equity Incentive Plan 2013 [Member] | Consultant Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period							250,000
Equity Incentive Plan 2013 [Member] | Consultant Three [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period							300,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price							$ 1
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage							20.00%
Equity Incentive Plan 2013 [Member] | One Employee [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period				50,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price				$ 1.24
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage				20.00%
Equity Incentive Plan 2013 [Member] | Four Directors [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period							1,050,000
Equity Incentive Plan 2013 [Member] | Four Directors And Consultant Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price							$ 1

Common and Preferred Stock Re32

Common and Preferred Stock Reserved for Future Issuances: (Details)	Sep. 30, 2015shares
Class of Stock [Line Items]
Common Stock Reserved	25,869,278
Common Stock Warrant Outstanding [Member]
Class of Stock [Line Items]
Common Stock Reserved	1,375,432
Common Stock Option Outstanding [Member]
Class of Stock [Line Items]
Common Stock Reserved	7,737,952
Conversion of Series A Preferred Stock [Member]
Class of Stock [Line Items]
Common Stock Reserved	16,755,894

Common and Preferred Stock Re33

Common and Preferred Stock Reserved for Future Issuances: (Details Textual) - shares	Feb. 09, 2015	Sep. 30, 2015	Dec. 31, 2014
Conversion of Stock, Shares Converted		4,607,106	1,637,000
Warrant Holder [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	1,325,000
Series A Preferred Stock [Member] | Warrant Holder [Member]
Conversion of Stock, Shares Converted	1,325,000

Subsequent Events_ (Details Tex

Subsequent Events: (Details Textual) - USD ($)	Nov. 05, 2015	Oct. 09, 2015	Nov. 13, 2015	Sep. 30, 2015	Dec. 31, 2014
Subsequent Event [Line Items]
Conversion of Stock, Shares Converted				4,607,106	1,637,000
Subsequent Event [Member]
Subsequent Event [Line Items]
Estimated Budget For Services		$ 11,600,000
Payments for Advance to Affiliate		$ 200,000
Service Fees	$ 928,000
Pass Through Expenses	268,000
Investigator And Institute fees	$ 680,000
Subsequent Event [Member] | Series A Preferred Stock [Member]
Subsequent Event [Line Items]
Stock Issued During Period, Shares, Conversion of Convertible Securities			99,000
Subsequent Event [Member] | Series A Preferred Stock [Member] | Warrant Holder [Member]
Subsequent Event [Line Items]
Conversion of Stock, Shares Converted			99,000